GABA A receptor agonist - Pipeline Insight, 2024

GABA A receptor agonist - Pipeline Insight, 2024

DelveInsight’s, “GABA A receptor agonist - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in GABA A receptor agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

GABA A receptor agonist Understanding

GABA A receptor agonist: Overview

Type-A γ-aminobutyric acid receptors (GABAARs) are the principal mediators of rapid inhibitory synaptic transmission in the human brain. A decline in GABAAR signalling triggers hyperactive neurological disorders such as insomnia, anxiety and epilepsy. GABAARs are the targets of a wide range of drugs including benzodiazepines, used in the treatment of epilepsy, insomnia, anxiety and panic disorder, and the intravenous general anaesthetics propofol and etomidate. GABAARs also mediate alcohol inebriation and are targets for endogenous modulators such as neurosteroids.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence GABA A receptor agonist R&D. The therapies under development are focused on novel approaches for GABA A receptor agonist.

GABA A receptor agonist Emerging Drugs Chapters

This segment of the GABA A receptor agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

GABA A receptor agonist Emerging Drugs

• Ganaxolone: Marinus Pharmaceuticals

Ganaxolone is a GABAA receptor modulator that acts by regulating brain activity. This process can include inhibiting the abnormal electrical discharges that cause seizures and status epilepticus or restoring balance in disrupted neuronal activity in other neurologic and psychiatric disorders. GABA is the chief inhibitory neurotransmitter in the brain. Ganaxolone binds to one of the receptor subtypes, the GABAA receptor. When this receptor is activated, it increases the movement of chloride ions through a pore on the cell surface. This action changes the positive and negative charges inside and outside the cell, which inhibits the firing of the neuron. Ganaxolone is an analogue of the naturally occurring neurosteroid, allopregnanolone. Neurosteroids do not possess the metabolic effects of other steroids; rather, they regulate the balance of excitatory and inhibitory brain activity. Ganaxolone has been designed with an added methyl group that prevents back-conversion to an active steroid intended to better maintain its specific neuromodulatory activity.

• Padsevonil: UCB Biopharma

Padsevonil is a dual-acting antiepileptic drug that has a mechanism of action designed specifically to interact with pre- and post-synaptic targets. Presynaptically, it binds with high affinity to the three isoforms of synaptic vesicle protein 2: SV2A, SV2B and SV2C. Postsynaptically, it binds with moderate affinity to the benzodiazepine recognition site on the GABAA receptor, where it acts as a partial agonist. Previous results of a Phase II proof-of-concept study demonstrated that treatment with padsevonil may be associated with a clinically meaningful reduction in focal seizure frequency and suggested an acceptable tolerability/safety profile. It is currently in Phase II/III stage of development (NCT03370120).

Further product details are provided in the report……..

GABA A receptor agonist: Therapeutic Assessment

This segment of the report provides insights about the different GABA A receptor agonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on GABA A receptor agonist

There are approx. 10+ key companies which are developing the GABA A receptor agonist. The companies which have their GABA A receptor agonist drug candidates in the most advanced stage, i.e. Phase III include, Marinus Pharmaceuticals.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

GABA A receptor agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

GABA A receptor agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses GABA A receptor agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA A receptor agonist drugs.

GABA A receptor agonist Report Insights

• GABA A receptor agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

GABA A receptor agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing GABA A receptor agonist drugs?
• How many GABA A receptor agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for GABA A receptor agonist?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GABA A receptor agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for GABA A receptor agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Marinus Pharmaceuticals
• UCB Biopharma
• Confluence Pharmaceuticals
• Cerevel Therapeutics
• Sichuan Haisco Pharmaceutical
• Ovid Therapeutics

Key Products

• Ganaxolone
• Padsevonil
• Acamprosate
• Darigabat
• Ciprofol
• OV101